SRPT公司概览
盘中时间采用ET。市场数据可能有所延迟。
公司概况
公司网站Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
- 行业
- Biotechnology
- 部门
- Healthcare
- 总部
- US
- 首席执行官
- Michael E. Severino
- 上市以来
- 1997年6月4日
- 雇员
- 835
市场位置
日内区间
当前US$17.44
52周区间
当前US$17.44
- 开盘价
- US$17.86
- 前收盘价
- US$17.85
- 成交量
- 328.12万
- 1.03× 平均值
- 平均成交量
- 319.12万
- 日均成交量
- 市值
- 18.41亿 USD
- 贝塔
- 0.21
- 市场参考 1
- 50天平均值
- US$19.1124
- 低于平均水平-8.75%
- 200天平均值
- US$19.0042
- 低于平均水平-8.23%
